Bradley J. Monk, MD
The development of targeted therapies, including bevacizumab (Avastin) and 3 PARP inhibitors, is changing treatment paradigms for women with epithelial ovarian cancer. This underscores the need to personalize care and conduct molecular testing, according to experts.
Epithelial ovarian cancer remains the most lethal gynecologic malignancy. Although it is highly sensitive to platinum-based chemotherapy and many patients achieve remission, most will experience disease recurrence. Use of bevacizumab and PARP inhibitors, however, enables more patients with this disease to achieve long-term responses and possibly even cures.
During an OncLive Peer Exchange®
program at the 2019 Society of Gynecologic Oncology Annual Meeting in March, a panel of ovarian cancer experts discussed how they use these agents in their own practices.
A consistent refrain during the discussion: “Leave no one behind.”
... to read the full story